What it's for (Indications)
- Bromocriptine is a dopamine receptor agonist primarily utilized in the management of several endocrine and neurological conditions.
- Its primary indications include the treatment of hyperprolactinemia, whether idiopathic or associated with pituitary adenomas (prolactinomas), which can manifest as galactorrhea, amenorrhea, or infertility.
- It is also indicated for the symptomatic treatment of Parkinson's disease, both as monotherapy in early stages or as an adjunct to levodopa in more advanced cases to manage motor fluctuations and improve motor symptoms.
- Furthermore, bromocriptine is used in the treatment of acromegaly to reduce elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels when surgery or radiation therapy are not feasible or have been unsuccessful, or as an adjunctive therapy.
- A specific quick-release formulation (e.
- g.
- , Cycloset®) is also indicated for the improvement of glycemic control in adults with type 2 diabetes mellitus, particularly when taken in the morning to optimize metabolic pathways.
- This broad utility underscores its significant role in clinical practice for distinct physiological dysfunctions requiring dopaminergic modulation.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of bromocriptine is highly individualized and must be carefully titrated based on the patient's specific condition, response to treatment, and tolerability, always aiming for the lowest effective dose to minimize adverse effects. For hyperprolactinemic states, treatment typically initiates with a low dose, such as 1.25 mg daily at bedtime, gradually increasing by 1.25 mg every 3-7 days to an average therapeutic range of 2.5-15 mg/day, administered in divided doses with meals. In Parkinson's disease, the starting dose is usually 1.25 mg two to three times daily, with increments of 2.5 mg every 14-28 days as tolerated, with the total daily dosage often ranging from 10-30 mg, although higher doses up to 100 mg have been used in specific cases under close supervision. For acromegaly, a starting dose of 1.25 mg daily at bedtime may be increased progressively to 20-30 mg/day in divided doses. For type 2 diabetes mellitus (Cycloset formulation), the recommended starting dose is 0.8 mg once daily in the morning, which may be increased weekly to a maximum of 4.8 mg/day. All dose adjustments should be performed under close medical supervision to minimize side effects and optimize therapeutic outcomes. |
Safety & Warnings
Common Side Effects
- Bromocriptine can cause a range of side effects, some of which can be significant and require careful monitoring.
- Commonly reported adverse reactions include nausea, vomiting, constipation, headache, dizziness, drowsiness, and postural hypotension, especially during the initial titration phase due to its vascular effects.
- These gastrointestinal and cardiovascular effects can often be mitigated by starting with a low dose and gradual incrementation, or by administering the drug with food.
- More serious, albeit less common, side effects encompass neuropsychiatric disturbances such as hallucinations, delusions, confusion, and psychosis, particularly in patients with a history of such conditions or at higher doses.
- Impulse control disorders, including pathological gambling, hypersexuality, compulsive shopping, and binge eating, have also been reported in patients treated with dopamine agonists.
- Sudden onset of sleep, sometimes without warning, can occur and poses a significant safety risk for patients engaged in activities like driving or operating machinery.
- Long-term, high-dose therapy, particularly in the treatment of acromegaly, has been associated with serious fibrotic complications such as pulmonary infiltrates, pleural effusions, pleural fibrosis, and retroperitoneal fibrosis.
- Other potential adverse effects include erythromelalgia and, rarely, cerebrovascular events, particularly in postpartum women.
Serious Warnings
- Black Box Warning: Serious Warnings: Bromocriptine treatment warrants careful consideration of several serious risks, particularly concerning cardiovascular and neuropsychiatric safety. Patients, especially postpartum women, receiving bromocriptine for the suppression of lactation have experienced rare but serious cardiovascular events, including hypertension, myocardial infarction, seizures, and cerebrovascular accidents. Therefore, its use for lactation suppression is generally discouraged in favor of non-pharmacological methods due to these risks and the availability of safer alternatives. Patients with a history of severe psychiatric disorders or those exhibiting new psychiatric symptoms such as hallucinations, delusions, or confusion during treatment require immediate re-evaluation and potential discontinuation, as bromocriptine can exacerbate or induce these conditions. Impulse control disorders, including pathological gambling, hypersexuality, compulsive shopping, and binge eating, have been reported in patients treated with dopamine agonists, including bromocriptine; clinicians should regularly assess patients for the emergence of these behaviors. Additionally, patients should be warned about the potential for sudden onset of sleep, which can occur without warning at any time during the day, even after initial dosage stabilization, necessitating extreme caution when driving or operating machinery. Long-term, high-dose therapy, particularly for acromegaly, has been associated with pleural and pericardial effusions, as well as retroperitoneal fibrosis, requiring careful monitoring for respiratory or cardiac symptoms and potential drug discontinuation if such conditions develop or worsen.
- Bromocriptine treatment necessitates careful consideration of several serious risks, particularly concerning cardiovascular and neuropsychiatric safety.
- Patients, especially postpartum women, receiving bromocriptine for the suppression of lactation have experienced rare but serious cardiovascular events, including hypertension, myocardial infarction, seizures, and cerebrovascular accidents.
- Therefore, its use for lactation suppression is generally discouraged in favor of non-pharmacological methods due to these risks and the availability of safer alternatives.
- Patients with a history of severe psychiatric disorders or those exhibiting new psychiatric symptoms such as hallucinations, delusions, or confusion during treatment require immediate re-evaluation and potential discontinuation, as bromocriptine can exacerbate or induce these conditions.
- Impulse control disorders, including pathological gambling, hypersexuality, compulsive shopping, and binge eating, have been reported in patients treated with dopamine agonists, including bromocriptine; clinicians should regularly assess patients for the emergence of these behaviors.
- Additionally, patients should be warned about the potential for sudden onset of sleep, which can occur without warning at any time during the day, even after initial dosage stabilization, necessitating extreme caution when driving or operating machinery.
- Long-term, high-dose therapy, particularly for acromegaly, has been associated with pleural and pericardial effusions, as well as retroperitoneal fibrosis, requiring careful monitoring for respiratory or cardiac symptoms and potential drug discontinuation if such conditions develop or worsen.
- Caution is also advised in patients with hepatic or renal impairment, as drug clearance may be affected.
How it Works (Mechanism of Action)
Bromocriptine exerts its therapeutic effects primarily as a potent dopamine D2 receptor agonist. By stimulating these receptors, particularly in the anterior pituitary gland, it effectively inhibits the secretion of prolactin, a hormone responsible for lactation, thereby reducing hyperprolactinemia, galactorrhea, and restoring normal menstrual cycles and fertility in affected individuals. In the context of Parkinson's disease, bromocriptine's agonistic action on D2 receptors in the striatum helps to compensate for the deficiency of endogenous dopamine, thus ameliorating motor symptoms like tremor, rigidity, and bradykinesia. For acromegaly, it reduces the secretion of growth hormone (GH) from the pituitary by activating dopamine D2 receptors on somatotrophs, which are inhibitory to GH release. The specific quick-release formulation used for type 2 diabetes mellitus (Cycloset®) is thought to act by resetting abnormally elevated hypothalamic dopaminergic tone, which in turn improves insulin sensitivity and reduces hepatic glucose production. This proposed mechanism is believed to target circadian neuroendocrine activity to normalize metabolic function, and appears to be independent of its prolactin-lowering effects at the doses used for diabetes management, suggesting a distinct pathway for its metabolic benefits. Its multifaceted actions across different receptor subtypes and brain regions contribute to its diverse clinical utility.